Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Flavia Sunzini

Showing results (1-10 of 18) with videos related to

Pageof 2
Sort By:
Therapeutic Advances in Musculoskeletal Disease|July 14, 2020
JAK inhibitors and infections risk: focus on herpes zosterFlavia Sunzini, Iain McInnes, Stefan Siebert
Arthritis & Rheumatology (Hoboken, N.J.)|January 4, 2023
The Biology of Pain: Through the Rheumatology LensFlavia Sunzini, Andrew Schrepf, Daniel J Clauw, et al.
International Journal of Molecular Sciences|February 15, 2020
Hydrogen Sulfide as Potential Regulatory <i>Gasotransmitter</i> in Arthritic DiseasesFlavia Sunzini, Susanna De Stefano, Maria Sole Chimenti, et al.
International Journal of Molecular Sciences|August 29, 2020
Correction: Flavia, F., et al. Hydrogen Sulfide as a Potential Regulatory <i>Gasotransmitter</i> in Arthritic Diseases. <i>Int. J. Mol. Sci.</i> 2020, <i>21</i>, 1180; doi:10.3390/ijms21041180Flavia Sunzini, Susanna De Stefano, Maria Sole Chimenti, et al.
The Journal of International Medical Research|September 30, 2016
Remission and low disease activity in a cohort of real-life patients with rheumatoid arthritis treated with first-line antitumour necrosis factorPaola Conigliaro, Maria Sole Chimenti, Paola Triggianese, et al.
The Israel Medical Association Journal : IMAJ|August 22, 2017
Factors Predicting 2 Years of Remission and Low Disease Activity in Rheumatoid Arthritis Patients Treated with TNF-inhibitorsPaola Conigliaro, Paola Triggianese, Maria S Chimenti, et al.
Expert Opinion on Biological Therapy|December 1, 2022
What's new and what's next for biological and targeted synthetic treatments in psoriatic arthritis?Flavia Sunzini, Arianna D'Antonio, Mauro Fatica, et al.
Annals of the Rheumatic Diseases|March 11, 2021
TNF is a homoeostatic regulator of distinct epigenetically primed human osteoclast precursorsCecilia Ansalone, John Cole, Sabarinadh Chilaka, et al.
Rheumatology (Oxford, England)|March 31, 2021
Apremilast inhibits inflammatory osteoclastogenesisYannick Degboé, Flavia Sunzini, Shatakshi Sood, et al.
Autoimmunity Reviews|May 7, 2019
Challenges in the treatment of Rheumatoid ArthritisPaola Conigliaro, Paola Triggianese, Erica De Martino, et al.
Pageof 2

Showing results (1-10 of 18) with videos related to

Sort By:
Pageof 2
Therapeutic Advances in Musculoskeletal Disease|July 14, 2020
JAK inhibitors and infections risk: focus on herpes zosterFlavia Sunzini, Iain McInnes, Stefan Siebert
Arthritis & Rheumatology (Hoboken, N.J.)|January 4, 2023
The Biology of Pain: Through the Rheumatology LensFlavia Sunzini, Andrew Schrepf, Daniel J Clauw, et al.
International Journal of Molecular Sciences|February 15, 2020
Hydrogen Sulfide as Potential Regulatory <i>Gasotransmitter</i> in Arthritic DiseasesFlavia Sunzini, Susanna De Stefano, Maria Sole Chimenti, et al.
International Journal of Molecular Sciences|August 29, 2020
Correction: Flavia, F., et al. Hydrogen Sulfide as a Potential Regulatory <i>Gasotransmitter</i> in Arthritic Diseases. <i>Int. J. Mol. Sci.</i> 2020, <i>21</i>, 1180; doi:10.3390/ijms21041180Flavia Sunzini, Susanna De Stefano, Maria Sole Chimenti, et al.
The Journal of International Medical Research|September 30, 2016
Remission and low disease activity in a cohort of real-life patients with rheumatoid arthritis treated with first-line antitumour necrosis factorPaola Conigliaro, Maria Sole Chimenti, Paola Triggianese, et al.
The Israel Medical Association Journal : IMAJ|August 22, 2017
Factors Predicting 2 Years of Remission and Low Disease Activity in Rheumatoid Arthritis Patients Treated with TNF-inhibitorsPaola Conigliaro, Paola Triggianese, Maria S Chimenti, et al.
Expert Opinion on Biological Therapy|December 1, 2022
What's new and what's next for biological and targeted synthetic treatments in psoriatic arthritis?Flavia Sunzini, Arianna D'Antonio, Mauro Fatica, et al.
Annals of the Rheumatic Diseases|March 11, 2021
TNF is a homoeostatic regulator of distinct epigenetically primed human osteoclast precursorsCecilia Ansalone, John Cole, Sabarinadh Chilaka, et al.
Rheumatology (Oxford, England)|March 31, 2021
Apremilast inhibits inflammatory osteoclastogenesisYannick Degboé, Flavia Sunzini, Shatakshi Sood, et al.
Autoimmunity Reviews|May 7, 2019
Challenges in the treatment of Rheumatoid ArthritisPaola Conigliaro, Paola Triggianese, Erica De Martino, et al.
Pageof 2